Actively Recruiting

Phase 4
Age: 18Years +
FEMALE
ID04730609

Dexmedetomidine for Treatment of Shivering During Scheduled Elective Cesarean Delivery: Determining the Optimal Dose

Led by Mayo Clinic · Updated on 2025-09-11

40

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying the best dose of Dexmedetomidine to stop shivering in women undergoing scheduled elective cesarean deliveries. This trial focuses on patients who experience moderate to severe shivering during surgery and aims to find the dose that stops shivering in 90% of these patients within 5 minutes. The study uses a phase 4 design to evaluate this dosing in a real clinical setting. Participants who experience Grade 3 or 4 shivering during their cesarean delivery under spinal anesthesia will receive Dexmedetomidine intravenously. The dose for each patient will be determined using a sequential up-and-down method with a biased coin design, starting with an initial dose of 10 mcg. An anesthesia physician not involved in patient care prepares the drug to maintain objectivity. Spinal anesthesia is given with standard doses of bupivacaine, fentanyl, and morphine. During the study, shivering is graded using a five-point scale from no shivering to full body muscle activity. Researchers will monitor the effect of the drug on shivering within 5 minutes of administration while tracking maternal heart rate and dose amounts during surgery. The trial includes pre-operative screening, drug administration during the operation, and ongoing observation of responses. Participation ends after the intraoperative course, and safety is monitored throughout.

CONDITIONS

Brief Title

Dexmedetomidine for Intraoperative Shivering in Scheduled Elective Cesarean Delivery

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Women presenting for planned cesarean delivery
  • American Society of Anesthesiology Physical Classification Status 2 or 3 without major medical co-morbidities
  • Singleton pregnancy in the third trimester (28-42 weeks gestation)
  • Use of spinal anesthesia technique
Not Eligible

You will not qualify if you...

  • Contraindication to spinal anesthesia technique
  • Allergy or intolerance to dexmedetomidine or clonidine
  • Oral temperature below 36 degrees Celsius before the procedure
  • Unable to give personal consent
  • Preterm premature rupture of membranes or infection concerns such as chorioamnionitis
  • Conversion to general anesthesia before randomization
  • Use of sedative medications (fentanyl, midazolam, ketamine, nitrous oxide) before randomization

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - During the intraoperative course

Participants receive intravenous dexmedetomidine during scheduled elective cesarean delivery if they experience Grade 3 or 4 shivering at delivery. The dose is adjusted using a sequential up-and-down method to find the optimal dose for stopping shivering within 5 minutes.

1 treatment visit (in-person) during cesarean delivery

Trial Site Locations

Total: 1 location

1

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

Loading map...

Research Team

H

Hans P Sviggum, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here